Effect of Anti-TGF-β Treatment in a Mouse Model of Severe Osteogenesis Imperfecta.
Animals
Antibodies, Neutralizing
/ pharmacology
Bone and Bones
/ metabolism
Disease Models, Animal
Extracellular Matrix Proteins
/ deficiency
Mice
Mice, Knockout
Molecular Chaperones
/ metabolism
Osteogenesis
/ drug effects
Osteogenesis Imperfecta
/ drug therapy
Transforming Growth Factor beta
/ antagonists & inhibitors
ANIMAL MODEL
BONE
OSTEOGENESIS IMPERFECTA
RARE BONE DISEASES
TGF-ß
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
04
06
2018
revised:
09
10
2018
accepted:
16
10
2018
pubmed:
26
10
2018
medline:
28
5
2020
entrez:
26
10
2018
Statut:
ppublish
Résumé
Osteogenesis imperfecta (OI) is a heritable bone fragility disorder that is usually caused by mutations affecting collagen type I encoding genes. Recent studies in mouse models of recessive OI, Crtap
Substances chimiques
Antibodies, Neutralizing
0
Crtap protein, mouse
0
Extracellular Matrix Proteins
0
Molecular Chaperones
0
Transforming Growth Factor beta
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-214Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 American Society for Bone and Mineral Research.